KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Accumulated Depreciation & Amortization (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Accumulated Depreciation & Amortization data on record, last reported at $43.6 million in Q1 2025.

  • For Q1 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $43.6 million; the TTM value through Mar 2025 reached $43.6 million, changed N/A, while the annual FY2024 figure was $43.5 million, 1.44% up from the prior year.
  • Accumulated Depreciation & Amortization reached $43.6 million in Q1 2025 per AQST's latest filing, roughly flat from $43.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $43.6 million in Q1 2025 and bottomed at $39.9 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $42.2 million, with a median of $42.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: dropped 2.49% in 2021, then grew 5.28% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $39.9 million in 2021, then grew by 5.28% to $42.0 million in 2022, then rose by 2.19% to $42.9 million in 2023, then increased by 1.44% to $43.5 million in 2024, then rose by 0.31% to $43.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $43.6 million in Q1 2025, $43.5 million in Q4 2024, and $43.4 million in Q3 2024.